ITGAX and neoplasm: Immune analyses at the endpoint showed that ZCVCT26@D‐Gel, with its capability to induce pseudo‐oncolysis in tumor cells upon bioorthogonal anchoring, resulted in higher frequencies of CD80+CD86+CD11c+ mature DCs in tumor‐draining lymph nodes (TDLNs) (Figure 4F).